Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mHCC - 1st line (L1), ... vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 459, 2019 (REV) 1.18 [0.99; 1.40]
HIMALAYA, 2022 (REV) 1.28 [1.07; 1.53]
IMbrave-150, 2020 (REV) 1.72 [1.26; 2.36]
ORIENT-32, 2021 (REV) 1.75 [1.33; 2.32]
1.41 [1.17 ; 1.71 ] CheckMate 459, 2019 (REV), HIMALAYA, 2022 (REV), IMbrave-150, 2020 (REV), ORIENT-32, 2021 (REV) 4 64% 2,597 low not evaluable deaths (OS) (extension)detailed results CheckMate 459, 2019 (REV) 1.18 [1.00; 1.39]
HIMALAYA, 2022 (REV) 1.28 [1.09; 1.50]
1.23 [1.10 ; 1.38 ] CheckMate 459, 2019 (REV), HIMALAYA, 2022 (REV) 2 0% 1,525 low not evaluable progression or deaths (PFS)detailed results CheckMate 459, 2019 (REV) 1.08 [0.91; 1.27]
HIMALAYA, 2022 (REV) 1.11 [0.95; 1.30]
IMbrave-150, 2020 (REV) 1.69 [1.33; 2.16]
1.24 [0.98 ; 1.59 ] CheckMate 459, 2019 (REV), HIMALAYA, 2022 (REV), IMbrave-150, 2020 (REV) 3 81% 2,026 moderate not evaluable objective responses (ORR)detailed results CheckMate 459, 2019 (REV) 0.41 [0.25; 0.67]
IMbrave-150, 2020 (REV) 0.36 [0.21; 0.62]
0.39 [0.27 ; 0.56 ] CheckMate 459, 2019 (REV), IMbrave-150, 2020 (REV) 2 0% 1,244 moderate not evaluable AE (any grade)detailed results HIMALAYA, 2022 (REV) 0.56 [0.25; 1.23]
IMbrave-150, 2020 (REV) 1.43 [0.29; 7.17]
ORIENT-32, 2021 (REV) 1.84 [0.95; 3.58]
1.11 [0.46 ; 2.64 ] HIMALAYA, 2022 (REV), IMbrave-150, 2020 (REV), ORIENT-32, 2021 (REV) 3 62% 1,812 low not evaluable AE (grade 3-4)detailed results HIMALAYA, 2022 (REV) 0.41 [0.31; 0.56]
IMbrave-150, 2020 (REV) 0.94 [0.64; 1.39]
ORIENT-32, 2021 (REV) 1.09 [0.76; 1.58]
0.75 [0.40 ; 1.41 ] HIMALAYA, 2022 (REV), IMbrave-150, 2020 (REV), ORIENT-32, 2021 (REV) 3 90% 1,812 low not evaluable AE leading to death (grade 5)detailed results HIMALAYA, 2022 (REV) 0.93 [0.54; 1.59]
IMbrave-150, 2020 (REV) 1.28 [0.55; 3.00]
ORIENT-32, 2021 (REV) 0.34 [0.04; 2.83]
0.97 [0.62 ; 1.52 ] HIMALAYA, 2022 (REV), IMbrave-150, 2020 (REV), ORIENT-32, 2021 (REV) 3 0% 1,812 low not evaluable AE leading to treatment discontinuation (any grade)detailed results HIMALAYA, 2022 (REV) 1.28 [0.86; 1.90]
IMbrave-150, 2020 (REV) 0.62 [0.34; 1.13]
ORIENT-32, 2021 (REV) 0.40 [0.20; 0.78]
0.71 [0.35 ; 1.44 ] HIMALAYA, 2022 (REV), IMbrave-150, 2020 (REV), ORIENT-32, 2021 (REV) 3 80% 1,812 low not evaluable SAE (any grade)detailed results IMbrave-150, 2020 (REV) 0.73 [0.48; 1.09]
0.73 [0.48 ; 1.09 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable STRAE (grade 3-4)detailed results CheckMate 459, 2019 (REV) 3.32 [2.41; 4.57]
3.32 [2.41 ; 4.57 ] CheckMate 459, 2019 (REV) 1 0% 743 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 459, 2019 (REV) 1.88 [1.00; 3.52]
1.88 [1.00 ; 3.52 ] CheckMate 459, 2019 (REV) 1 0% 743 NA not evaluable Abdominal pain AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 2.14 [0.53; 8.66]
2.14 [0.53 ; 8.66 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Acute kidney injury AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 6.43 [0.66; 62.33]
6.43 [0.66 ; 62.33 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Alopecia AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 2.11 [0.04; 106.97]
2.11 [0.04 ; 106.97 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Anaemia AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 0.94 [0.28; 3.09]
0.94 [0.28 ; 3.09 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Asthenia AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 8.63 [0.96; 77.88]
8.63 [0.96 ; 77.88 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Constipation AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 2.11 [0.04; 106.97]
2.11 [0.04 ; 106.97 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Cough AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 4.24 [0.14; 127.03]
4.24 [0.14 ; 127.03 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Decreased appetite AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 3.25 [0.90; 11.69]
3.25 [0.90 ; 11.69 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Diarrhoea AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 2.91 [0.99; 8.54]
2.91 [0.99 ; 8.54 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Dyspepsia AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 8.53 [0.38; 190.34]
8.53 [0.38 ; 190.34 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Dyspnoea AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 1.59 [0.35; 7.21]
1.59 [0.35 ; 7.21 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Epistaxis AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 4.24 [0.14; 127.03]
4.24 [0.14 ; 127.03 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Fatigue AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 1.33 [0.43; 4.13]
1.33 [0.43 ; 4.13 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Hypertension AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 0.77 [0.44; 1.36]
0.77 [0.44 ; 1.36 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Increase AST AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 0.72 [0.31; 1.65]
0.72 [0.31 ; 1.65 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Increased ALT AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 0.34 [0.08; 1.55]
0.34 [0.08 ; 1.55 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Infusion-related reaction AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 0.13 [0.01; 2.26]
0.13 [0.01 ; 2.26 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Nausea AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 2.12 [0.13; 34.06]
2.12 [0.13 ; 34.06 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 59.73 [3.52; 1013.60]
59.73 [3.52 ; 1013.60 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Proteinuria AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 0.21 [0.03; 1.62]
0.21 [0.03 ; 1.62 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Pruritus AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 2.11 [0.04; 106.97]
2.11 [0.04 ; 106.97 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Pyrexia AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 1.06 [0.19; 5.82]
1.06 [0.19 ; 5.82 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Rash AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 17.29 [0.91; 329.11]
17.29 [0.91 ; 329.11 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 1.06 [0.26; 4.28]
1.06 [0.26 ; 4.28 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Vomiting AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 1.05 [0.09; 11.72]
1.05 [0.09 ; 11.72 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable Weight decreased AE (grade 3-4)detailed results IMbrave-150, 2020 (REV) 4.24 [0.14; 127.03]
4.24 [0.14 ; 127.03 ] IMbrave-150, 2020 (REV) 1 0% 485 NA not evaluable 0.0 100.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-03 06:57 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 131
- treatments: 670